A bit more!
$Tenaya Therapeutics(TNYA.US$ Joseph Pantginis has given a Buy rating to Tenaya Therapeutics based on a number of factors. First and foremost, Pantginis highlights the FDA’s approval of Tenaya’s IND application for TN-401, an AAV9-based gene therapy aimed at treating arrhythmogenic right ventricular cardiomyopathy (ARVC). The clearance by the FDA to initiate clinical testing is seen as a significant step forward. Additionally, Tenaya’s plans to commence the RIDGE-1 Phase 1b trial, which will focus on assessing TN-401’s safety and clinical effectiveness in PKP2-associated ARVC patients, also contributed to Pantginis’s favorable rating.
Furthermore, the report emphasizes that Tenaya has produced enough cGMP grade TN-401 to fully support and complete the entire study. Pantginis also mentions the robust preclinical data backing TN-401’s potential efficacy in ARVC. Moreover, he takes note of the promising updates surrounding Tenaya’s other leading assets, TN-301 and TN-201. The data from these assets provides insight into their dosing, safety, and target engagement, which has also factored into Pantginis’s positive rating for Tenaya Therapeutics.
In another report released on October 17, Piper Sandler also assigned a Buy rating to the stock with a $40.00 price target.![]()
Furthermore, the report emphasizes that Tenaya has produced enough cGMP grade TN-401 to fully support and complete the entire study. Pantginis also mentions the robust preclinical data backing TN-401’s potential efficacy in ARVC. Moreover, he takes note of the promising updates surrounding Tenaya’s other leading assets, TN-301 and TN-201. The data from these assets provides insight into their dosing, safety, and target engagement, which has also factored into Pantginis’s positive rating for Tenaya Therapeutics.
In another report released on October 17, Piper Sandler also assigned a Buy rating to the stock with a $40.00 price target.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
